Swedish Orphan Biovitrum (LSE:0MTD) - Stock Price, News & Analysis

0MTD Stock Overview

0MTD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	2/6
Dividends	0/6

Rewards

Cotiza un 66.9% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 21.59%

Risk Analysis

Tiene un alto nivel de endeudamiento

Los accionistas han sido diluidos en el último año

Swedish Orphan Biovitrum AB (publ) Competitors

Genus

LSE:GNS

UK£1.1b

NIOX Group

AIM:NIOX

UK£275.6m

Bioventix

AIM:BVXP

UK£237.5m

Hikma Pharmaceuticals

LSE:HIK

UK£4.1b

Price History & Performance

Summary of all time highs, changes and price drops for Swedish Orphan Biovitrum
Historical stock prices
Current Share Price	kr262.80
52 Week High	kr301.80
52 Week Low	kr197.90
Beta	0.27
1 Month Change	-6.40%
3 Month Change	-5.95%
1 Year Change	-0.43%
3 Year Change	87.21%
5 Year Change	23.15%
Change since IPO	257.69%

Recent updates

Shareholder Returns

	0MTD	GB Biotechs	GB Market
7D	-0.3%	-0.9%	-0.01%
1Y	-0.4%	-29.6%	0.8%

Rentabilidad frente al sector: 0MTD superó al sector UK Biotechs , que obtuvo un rendimiento del -27% el año pasado.

Rentabilidad vs. Mercado: 0MTD obtuvo unos resultados inferiores a los del mercado UK, que fue del 0.8% el año pasado.

Price Volatility

Is 0MTD's price volatile compared to industry and market?
0MTD volatility
0MTD Average Weekly Movement	4.4%
Biotechs Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0MTD no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0MTD (4%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
1939	1,772	Guido Oelkers	https://www.sobi.com

Swedish Orphan Biovitrum AB (publ), empresa biotecnológica integrada, investiga, desarrolla, fabrica y vende productos farmacéuticos en las áreas terapéuticas de hematología, inmunología y atención especializada en Europa, Norteamérica, Oriente Medio, Asia y Australia. Ofrece Alprolix para la hemofilia B; Aspaveli®/Empaveli para el tratamiento de pacientes adultos con hemoglobinuria paroxística nocturna; Doptelet para el tratamiento de la trombocitopenia; Elocta para la hemofilia A; Gamifant para la linfohistiocitosis hemofagocítica (HLH); VONJO para el tratamiento de adultos con mielofibrosis primaria o secundaria (post-policitemia vera o post-trombocitemia esencial) de riesgo intermedio o alto; Zynlonta, una enfermedad maligna agresiva; Kineret para el síndrome periódico asociado a la criopirina, la artritis reumatoide y la enfermedad de Still; Orfadin para tratar la tirosinemia hereditaria de tipo 1; y Synagis para infecciones graves de las vías respiratorias bajas. La empresa también suministra otros productos, como Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi y Waylivra.

Swedish Orphan Biovitrum AB (publ) Fundamentals Summary

How do Swedish Orphan Biovitrum's earnings and revenue compare to its market cap?
0MTD fundamental statistics
Market cap	kr89.02b
Earnings (TTM)	kr2.41b
Revenue (TTM)	kr22.12b

37.0x

P/E Ratio

4.0x

P/S Ratio

Is 0MTD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0MTD income statement (TTM)
Revenue	kr22.12b
Cost of Revenue	kr4.95b
Gross Profit	kr17.17b
Other Expenses	kr14.76b
Earnings	kr2.41b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)	7.09
Gross Margin	77.62%
Net Profit Margin	10.89%
Debt/Equity Ratio	59.6%

How did 0MTD perform over the long term?

See historical performance and comparison

0MTD Stock Overview

Rewards

Risk Analysis

Swedish Orphan Biovitrum AB (publ) Competitors

LSE:GNS

UK£1.1b

AIM:NIOX

UK£275.6m

AIM:BVXP

UK£237.5m

LSE:HIK

UK£4.1b

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Recent updates

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

New minor risk - Insider selling

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings released: EPS: kr0.30 (vs kr1.52 in 3Q 2022)

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings released: EPS: kr0.75 (vs kr0.87 in 2Q 2022)

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021)

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021)

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released: EPS: kr1.52 (vs kr1.60 in 3Q 2021)

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa

Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings released: EPS: kr0.87 (vs kr0.91 in 2Q 2021)

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi

Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member

First quarter 2022 earnings released: EPS: kr1.84 (vs kr2.36 in 1Q 2021)

Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study

Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH)

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022

Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others.

Investor sentiment deteriorated over the past week

Head of Technical Operations recently bought kr1.3m worth of stock

Third quarter 2021 earnings released: EPS kr1.60 (vs kr0.94 in 3Q 2020)

Swedish Orphan Biovitrum AB (publ) Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia

Nature Medicine Publishes Phase 3 Anakinra Study Results in Patients with Covid-19 Pneumonia